Lavoltidine (INN USAN BAN; code name AH-23844) previously known as loxtidine is a highly potent and selective H2 receptor antagonist which was under development as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
This page contains content from the copyrighted Wikipedia article "Loxtidine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
